The Daily Papule

Meeting abstracts

SID 2026

Society for Investigative Dermatology · Chicago, 13–16 May 2026

1,214 abstracts, published in JID on 21 July 2026. Their text is on the JID website.

  1. 0179

    Efficacy of dupilumab in Chinese atopic dermatitis patients: A real-world multicentre study

    Wang R, Li H, Wang Y

  2. 0184

    Rapid paradoxical worsening after dupilumab in ICI-associated eczematous dermatitis: Two cases

    Huang J, Yang J, … senior author Shen Y

  3. 0190

    Predicting psoriasis biologic therapy outcomes: An explainable hybrid machine-learning approach applying real-world data

    Hussain AB, Andrew T, … senior author Reynolds N

  4. 0192

    Streamlining prior authorization for dermatologic biologics: The role of centralized coordination

    Chau C, Klepser N, … senior author Lamb A

  5. 0196

    Variation in out-of-pocket expenditures for psoriasis biologic therapy

    Sun Q, Cohen J

  6. 0201

    Impact of biologic therapy on emergency department utilization in pediatric hidradenitis suppurativa patients: A TriNetX study

    Kherallah K, Chung CS, … senior author Lee KH

  7. 0229

    Frontal fibrosing alopecia with clinical improvement following dupilumab therapy: A case report

    Martin J, Skalka N, … senior author Asamoah E

  8. 0250

    Paradoxical resolution of generalized lichen nitidus in a pediatric patient in association with dupilumab

    Fernau E, Ricles V, … senior author Krakowski A

  9. 0270

    Therapeutic drug monitoring of infliximab in hidradenitis suppurativa

    Young A, Zhan X, … senior author Mi Q

  10. 0272

    Determinants of infliximab drug survival in hidradenitis suppurativa

    Young A, Zhan X, … senior author Mi Q

  11. 0284

    Evaluating the association between adalimumab use in hidradenitis suppurativa patients and psoriasiform events: A retrospective cohort study

    Park JH, Ramos-Briceño DA, … senior author Kaunitz G

  12. 0323

    Rituximab monotherapy versus combination immunosuppression in pemphigus vulgaris: An infection risk analysis

    Saksena S, Yang X, … senior author Werth VP

  13. 0331

    Dupilumab and psoriasis risk in patients with atopic dermatitis: A multicenter cohort study

    Block BR, Mehta J, … senior author Gulati N

  14. 0334

    Renal safety in psoriasis patients treated with biologics: Evidence from TriNetX

    Kim C, Roseman M, Wambold D

  15. 0346

    Surgical outcomes for hidradenitis suppurativa: Does biologic therapy make a difference?

    Kann R, Weitzner Y, … senior author Ciocon D

  16. 0369

    Effect of biologic therapy on psoriatic arthritis risk in children and young adults with psoriasis: A longitudinal cohort study

    Palma G, Cortes JA, … senior author Armstrong AW

  17. 0371

    Real-world prescribing patterns and racial disparities in treatment persistence for risankizumab in plaque psoriasis and psoriatic arthritis

    Ta K, Keller N, Dellavalle R

  18. 0407

    Biologic switching in psoriasis under a standardized national formulary: A veterans health administration cohort study

    Craver A, DeRycke E, … senior author Cohen J

  19. 0444

    Improvement of burning mouth syndrome associated with sjögren syndrome following treatment with nemolizumab

    Galaria A, Fritz S, … senior author Haque A

  20. 0461

    Anifrolumab is associated with lower infection risk and improved skin activity in refractory cutaneous lupus compared to conventional immunosuppressants

    Srikumar A, Urbanski N, Kang J

  21. 0470

    Dupilumab treatment restores skin barrier structure and function in patients aged 6 to 11 years with moderate-to-severe atopic dermatitis

    Cork MJ, Danby SG, … senior author Leung DY

  22. 0474

    Dupilumab improves itch and pain in epidermolysis bullosa: 52-week data

    Paller A, Bai I, … senior author Ren Z

  23. 0487

    Evaluating the efficacy and safety of dupilumab for chronic spontaneous urticaria

    Yu KE, Aboukhalil D, … senior author Sharma J

  24. 0497

    Adalimumab reduces epicardial adipose tissue in psoriasis: A post hoc analysis of a randomized placebo-controlled clinical trial

    Ramessur RR, Kernizan F, … senior author Gelfand J

  25. 0509

    Guselkumab improves quality of life outcomes in guttate and plaque psoriasis

    Kemeness C, Spangenberg A, … senior author Liao W

  26. 0512

    Guselkumab for the treatment of guttate and plaque psoriasis: A prospective trial

    Spangenberg A, Kemeness C, … senior author Liao W

  27. 0521

    Dupilumab reduces keloid dimensions and halts fibrosis

    Zhou J, Fiedler J, … senior author Guttman-Yassky E

  28. 0522

    Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review

    Alphonse C, Irfan M, … senior author Diaz AM

  29. 0532

    Real-world dupilumab outcomes in young children with atopic dermatitis

    Li A, Urbonas R, … senior author Wan J

  30. 0534

    Efficacy and safety of switching from reference ustekinumab to its biosimilar for the treatment of plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials

    Ghanem L, Cevallos-Cueva M, … senior author Montes de Oca Saucedo C

  31. 0539

    Barzolvolimab depletes cutaneous mast cells and mast cell–driven itch pathways in prurigo nodularis

    Nattkemper L, Coscarella G, Yosipovitch G

  32. 0550

    Risk of alopecia areata among rheumatoid arthritis and psoriasis patients treated with TNF inhibitors

    Ramos-Briceño DA, Park JH, … senior author Gonzalez AM

  33. 0551

    Augmented infliximab dosing in severe dissecting cellulitis

    Tan IJ, Trenholm IM, … senior author Cohen SR

  34. 0561

    A humanized mouse model of atopic dermatitis mirrors disease transcriptomics and is reversed by dupilumab

    Piccini I, Koudounas S, … senior author Bertolini M

  35. 0707

    Postmarketing safety analysis of bimekizumab for hidradenitis suppurativa

    Alomary SA, Baker N, … senior author Taylor SC

  36. 0712

    Cutaneous response to anifrolumab in black and non-black patients with cutaneous lupus erythematosus

    Zegeye Y, Fan E, Marano AL

  37. 0758

    Dupilumab receipt for atopic dermatitis among medicare beneficiaries differs by sex, race, and low-income subsidy status

    Takeshita J, Heintz J

  38. 0861

    Checkpoint inhibitor outcomes in melanoma are not driven by biologic sex in a large single center cohort

    Richmond RL, Micevic G

  39. 0951

    Pre-treatment serum proteomic panel to predict 16-week dupilumab response in atopic dermatitis

    Lally JS, Kenney H, … senior author Beck L

  40. 0992

    Pre-treatment cutaneous gene expression panel to predict 16-week dupilumab response in atopic dermatitis

    Kenney H, Lally J, … senior author Beck L

  41. 1013

    Serum biomarkers accurately differentiate dupilumab responders from nonresponders in atopic dermatitis

    Del Duca E, Zhou J, … senior author Guttman-Yassky E

  42. 1015

    Association of dupilumab-associated ocular surface disease with Th1/innate immune responses in tear fluid in atopic dermatitis patients

    Chu C, Cho Y, Chan T

  43. 1064

    Metabolomic analyses reveal metabolotypes that distinguish psoriasis patients by cutaneous disease severity and biologic therapy response

    Bergendorf A, Cohn E, … senior author Treichel A

  44. Late-breaking, LB1110

    Risk of type 2 inflammation-related diseases during IL-17-inhibitor treatment for psoriasis patients–A retrospective cohort stud

    Li B, Han Y, … senior author Zhao Y

  45. Late-breaking, LB1126

    High prevalence of tuberculosis and hepatitis B among patients with psoriasis and psoriatic arthritis starting biologics

    Bizuneh LG, Flores GO, … senior author Amerson E

  46. Late-breaking, LB1142

    Administration Behaviors for Injectable Biologics in Dermatology: A Multi-Center Survey Study

    McGowan Sullivan B, Ocejo S, … senior author Paller A

  47. Late-breaking, LB1147

    Cutaneous T-cell lymphoma risk by dupilumab indication: A multicenter cohort study

    Mehta J, Block BR, … senior author Gulati N

  48. Late-breaking, LB1152

    Efficacy of risankizumab on symptoms in patients with scalp psoriasis at week 52 in the UnlIMMited clinical trial

    Song EJ, Ezra N, … senior author Ackerman L

  49. Late-breaking, LB1204

    SPECTREM: Guselkumab lowers disease-related serum cytokines in low BSA, moderate psoriasis with high-impact sites

    Chen E, Cooper P, … senior author Panchakshari R

  50. Late-breaking, LB1221

    Profiling of severe refractory atopic dermatitis following failure of biologic and JAKi therapy

    Rault-Wang J, Schwartz R, … senior author Kibbie J